Filing Flows

Filing Flows › Prime Medicine (PRME) › Next earnings date

Prime Medicine (PRME) earnings on Nov 9, 2026: what to expect

Prime Medicine (PRME) is expected to report earnings on Nov 9, 2026 (estimated), tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.23 (−$0.28 to −$0.19, 13 estimates) on revenue of $1.1M, against −$0.32 and $1.2M a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 64% chance of beating next time.

Report dateNov 9, 2026 (estimated)
Days to go1
EPS estimate−$0.23
Revenue estimate$1.1M
Beat rate50%

What to watch

Last quarter (Q4 2025) the lines that make up revenue grew like this; the report shows whether the trend holds:

Prime Medicine: revenue lines, growth year over year, Q4 2025Prime Medicine: revenue lines, growth year over year, Q4 2025Revenue-62%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.32 on revenue of $1.3M, against the analysts' −$0.23.

The last report

Prime Medicine reported revenue of $838K for the fourth quarter 2025 (-62% Y/Y), net loss $46.1M. How it makes money → · Every quarter →

Prime Medicine: EPS against the estimate, last 4 reportsPrime Medicine: EPS against the estimate, last 4 reportsEstimateReported−$0.25−$0.32Nov 25−$0.26−$0.24Mar 26−$0.25−$0.28May 26−$0.26−$0.24Aug 26
Latest (Aug 26): Estimate −$0.26, Reported −$0.24.

Prime Medicine's latest quarter

Prime Medicine, Q4 2025: revenue $838K (-62% year over year), net loss $46.1M, operating cash flow −$37.3M. The chart follows the revenue to costs, profit and cash.

Questions

When does PRME report earnings?

Prime Medicine is expected to report on Nov 9, 2026 (estimated).

What are analysts expecting from Prime Medicine?

EPS of −$0.23 and revenue of $1.1M for the quarter.

Does Prime Medicine usually beat earnings?

It beat the consensus EPS estimate in 50% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.